Alnylam Pharmaceuticals (ALNY) Financial Analysis & Valuation | Quarter Chart
Alnylam Pharmaceuticals (ALNY)
ALNYPrice: $293.52
Fair Value: 🔒
🔒score
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hep... more
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and ... more
Description
Shares
| Market Cap | $39.19B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Yvonne L. Greenstreet |
| IPO Date | 2004-06-01 | CAGR | — |
| Employees | 2,230 | Website | www.alnylam.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
ALNY chart loading...
Fundamentals
Technicals
| Enterprise Value | $43.01B | P/E Ratio | 52.89 |
| Forward P/E | 21.62 | PEG Ratio | — |
| P/S Ratio | 9.02 | P/B Ratio | 35.79 |
| P/CF Ratio | 54 | P/FCF Ratio | 60.29 |
| EPS | $5.55 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | 82.57% | Gross Margin | 0.81% |
| Operating Margin | 0.18% | Profit Margin | 0.13% |
| ROE | 0.98% | ROA | 0.11% |
| ROCE | 0.2% | Current Ratio | 3.13 |
| Quick Ratio | 3.06 | Cash Ratio | 1.27 |
| Debt/Equity | 1.18 | Interest Coverage | 2.66 |
| Altman Z Score | 5.9 | Piotroski Score | 7 |